Ribomic

Ribomic Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Ribomic (4591.T) as of Oct 30, 2026 is 96.99 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 97.84 % — a change of -0.87% (lower).

Cash Conversion

96.99 %

YoY

-0.87%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Ribomic is 2026 96.99 % . Cash Conversion Rate (OCF/Net Income) of Ribomic was 2025 97.84 % . It decreases by -0.87% lower compared to the previous year.

The Ribomic Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2019
99.26 JPY
Jan 1, 2020
105.53 JPY
Jan 1, 2021
96.79 JPY
Jan 1, 2022
88.99 JPY
Jan 1, 2023
103.37 JPY
Jan 1, 2024
91.07 JPY
Jan 1, 2025
97.84 JPY
Jan 1, 2026
96.99 JPY
The Ribomic Cash Conversion history
YEARCash ConversionYoY
96.99 %-0.87%
97.84 %+7.44%
91.07 %-11.90%
103.37 %+16.16%
88.99 %-8.06%
96.79 %-8.28%
105.53 %+6.31%
99.26 %+7.59%
92.26 %-15.60%
109.32 %+8.86%
100.43 %-92.32%
1,306.89 %+1,603.37%
76.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

Cash Conversion Rate (OCF/Net Income) of Ribomic is 96.99 % in 2026.

Cash Conversion Rate (OCF/Net Income) of Ribomic changed from 97.84 % to 96.99 %, representing a -0.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Ribomic since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Ribomic with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Ribomic

All Key Metrics — Ribomic